Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: insights, disappointments and promise. Issue 2 (March 2019)

• Record Type: Journal Article
• Authors: Mannino, David M.
• Is Part Of: Current opinion in pulmonary medicine. Volume 25:Issue 2(2019:Mar.)
• Publication Date: 2019-03
• Subjects: biomarkers -- chronic obstructive pulmonary disease -- diagnosis -- exhaled breath -- lung function decline; Respiratory organs -- Diseases -- Periodicals; 616.24
• DOI: 10.1097/MCP.0000000000000549
• Languages: English
• ISSNs: 1070-5287

Abstract

Abstract : Purpose of review: This article reviews the status of biomarkers useful in the diagnosis and progression of chronic obstructive pulmonary disease (COPD). Biomarkers have been the focus of a great deal of COPD-related research in recent years, although useful markers in these specific arenas remain elusive. Recent findings: No biomarker other than lung function has been shown to be useful, to date, for the diagnosis of COPD. The best blood-based biomarkers for the progression of COPD may involve combinations of individual markers, such as CC16, fibrinogen and sRAGE. New imaging metrics, such as central airway collapse, pulmonary vascular changes and central airway branch variation, may be able to provide valuable prognostic and information, although these remain confined to research applications. Summary: Blood-based biomarkers for diagnosing and determining the progression of COPD remain disappointingly elusive. Although there have been some advances in nonblood-based markers, such as those from imaging, exhaled breath or physiologic assessment, these remain limited, for the most part, to research applications. Moving toward better markers that could be used in clinical application in the screening and diagnosis of COPD that could also provide prognostic information remains an important goal of research.